Lite Strategy (LITS) AI Stock Analysis

• Market Cap: $42.18M
• Dividend Yield: N/A
• Average Volume (3M): 261.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 81.20%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 36,362,000
• 10 Day Avg. Volume: 231,012
• 30 Day Avg. Volume: 261,028
• PEG Ratio: <0.01
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.68
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-24.81% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is primarily constrained by weak financial performance (sharp 2025 reversal to losses with zero revenue and sustained cash burn). Technical indicators are mostly neutral but do not offset the longer-term downtrend. Valuation is also pressured by loss-making results and no dividend support.

Positive Factors

Low Leverage

Zero reported debt in 2024–2025 and positive equity reduce financial distress risk and interest burden, giving management structural flexibility to pursue restructuring or strategic investments without immediate debt servicing constraints. This durability supports runway while cash burn is addressed.

Negative Factors

Sharp 2025 Revenue Collapse

A complete revenue cessation in 2025 and a $15.9M net loss indicate a structural operational or commercialization failure, removing recurring cash inflows and destroying operating leverage. This fundamentally weakens the business’ ability to self-sustain absent a credible recovery plan.

Lite Strategy Business Overview & Revenue Model

Company Description

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, In...

Read more

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, In...

Lite Strategy Financial Statement Overview

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	65.30M	48.82M	40.70M	34.80M
Gross Profit	0.00	-368.00K	65.30M	48.82M	40.70M	33.39M
EBITDA	-12.64M	-17.09M	25.82M	-36.38M	-75.16M	-41.02M
Net Income	-39.70M	-15.95M	17.78M	-31.84M	-54.45M	-41.31M
Balance Sheet
Total Assets	82.94M	18.29M	41.38M	120.81M	177.84M	174.10M
Cash, Cash Equivalents and Short-Term Investments	8.76M	18.01M	38.34M	100.69M	153.25M	153.43M
Total Debt	0.00	0.00	0.00	12.73M	9.64M	8.30M
Total Liabilities	1.09M	1.35M	8.36M	96.19M	125.43M	124.63M
Stockholders Equity	81.85M	16.93M	33.02M	24.62M	52.41M	49.47M
Cash Flow
Free Cash Flow	-12.16M	-20.84M	-50.48M	-52.52M	-49.23M	-32.67M
Operating Cash Flow	-12.16M	-20.84M	-50.47M	-52.48M	-48.75M	-31.96M
Investing Cash Flow	-99.43M	35.15M	49.14M	53.69M	6.89M	24.71M
Financing Cash Flow	96.61M	0.00	-11.87M	-40.00K	49.05M	3.47M

Lite Strategy Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.33
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Neutral. The current price of 1.33 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.14, and below the 200-day MA of 2.39, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.79 is Neutral, neither overbought nor oversold. The STOCH value of 61.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LITS.

Lite Strategy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	55 Neutral	$257.05M	-2.24	-129.98%	―	250.00%	15.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LITS	46 Neutral	$42.18M	-0.07	-68.86%	―	―	81.20%
GANX	46 Neutral	$76.04M	-5.27	-237.54%	―	―	42.29%
ABVC	45 Neutral	$36.38M	-6.26	-88.89%	―	56.52%	75.22%
JSPR	43 Neutral	$22.46M	-0.96	-191.12%	―	―	-24.38%

Lite Strategy Corporate Events